Search Results

reveal recognition motifs for the MRGPRD GPCR Chunyu Wang ,  Yongfeng Liu ,  Marion Lanier ,   Brian K ductal adenocarcinoma, β-blockers and antihistamines: A clinical trial is needed Jillian G Baker ,  Erica K Sloan ,   Kevin Pfleger ,  Peter J McCormick , Cristina Salmerón ,   Paul A Insel PGxDB: an interactive

Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid “You can try, try, try—and fail, fail, fail,” Eric says. Instead of chasing linear progress, Eric encourages young scientists to stay playful longer—embracing Eric and his team rejected the calcium route entirely. Eric is clear: real innovation requires real partnerships.

K., Gellman, S. H., Pautsch, A., Steyaert, J., Weis, W. I., & Kobilka, B. K. (2011). M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. I., Garcia, K. C., Wess, J., & Kobilka, B. K. (2013). D., Tworak, A., Watanabe, K., Pardon, E., Steyaert, J., Kandori, H., Katayama, K., Kiser, P. D., & Palczewski, K. (2023).

Focus on study of drugs and toxins on GPCR (opioid, cannabinoid receptor) and ion channel (K, Ca, TRP

receipt Selected donors are thanked publicly in podcast intros, videos, or events Donations above $20 K

Affiliations "Flynn, Helen R.2, Sampedro-Castaneda, Marisol1, Claxton, Suzanne1, Skehel, Mark2, Ultanir, Sila K.1